CCJ up +12.07% percent right now. $CCJ High is at 18.80 and

New Post Public Reply Private Reply Replies (0) Message Board

Nov 9, 2014 at 2:55 AM

CCJ up +12.07% percent right now. $CCJ High is at 18.80 and the Low 16.97 with current volume of 4,718,300.

Recent News posted below.

CCJ Cameco Corp Recent Headline News

Watch Out: Barbarians At The Gate For Cameco (CCJ)
at The Street - Fri Nov 07, 10:03AM CST
Trade-Ideas LLC identified Cameco (CCJ) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
CCJ: 18.75 (+2.02)

Uranium Hints at Quiet Renaissance in Post-Fukishima Nuclear Space
at The Street - Fri Nov 07, 5:05AM CST
Three years post-Fukushima, the price of uranium is finally showing signs of bottoming. Is the best still yet to come for those invested in the nuclear sector?
UUUU: 7.00 (+0.15), UEC: 1.72 (+0.25), CCJ: 18.75 (+2.02), BWC: 30.29 (-0.11), URRE: 1.94 (+0.37), DNN: 1.12 (+0.22), FLR: 66.29 (+0.62), URZ: 1.22 (+0.18)

Cameco Shares Down 12.7% Since SmarTrend's Sell Call (CCJ)
Comtex SmarTrend(R) - Thu Nov 06, 10:03AM CST
SmarTrend identified a Downtrend for Cameco (NYSE:CCJ) on August 7th, 2014 at $19.28. In approximately 3 months, Cameco has returned 12.66% as of today's recent price of $16.84.
CCJ: 18.75 (+2.02)

Skyharbour Identifies Basement Conductor Targets at Mann Lake Uranium Project in the Athabasca Basin, Saskatchewan
Marketwired - Mon Nov 03, 7:42AM CST
Skyharbour Resources Ltd. (TSX VENTURE: SYH)(OTC: SYHBF)(FRANKFURT:SC1N) (the "Company"

is pleased to announce it has successfully identified basement conductor targets in a setting proximal to other high-grade discoveries in the area at its 60% owned Mann Lake Uranium Project (the "Property"

. The Company recently completed its Phase 1 Field Program consisting of a ground-based electromagnetic (EM) survey on the property which is strategically located on the east side of the Athabasca Basin 25 km southwest of Cameco Corp's McArthur River Mine and 15 km northeast and along strike of Cameco's Millennium uranium deposit.
ABN.VN: 0.045 (+0.005), CCJ: 18.75 (+2.02)

Cameco Down 12.9% Since SmarTrend Downtrend Call (CCJ)
Comtex SmarTrend(R) - Thu Oct 30, 9:24AM CDT
SmarTrend identified a Downtrend for Cameco (NYSE:CCJ) on August 7th, 2014 at $19.28. In approximately 3 months, Cameco has returned 12.86% as of today's recent price of $16.80.
CCJ: 18.75 (+2.02)

Cameco (CCJ) Stock Drops After Reporting Quarterly Results
at The Street - Wed Oct 29, 2:36PM CDT
Shares of Cameco (CCJ) are falling Wednesday after the uranium producer missed analysts' estimates for revenue in the third quarter.
CCJ: 18.75 (+2.02)

Cameco reports third quarter financial results
Marketwired - Wed Oct 29, 7:32AM CDT
ALL AMOUNTS ARE STATED IN CDN $ (UNLESS NOTED)
CCJ: 18.75 (+2.02), CCO.TO: 21.24 (+2.11)

Is U.S. Silica (SLCA) Poised to Beat Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 3:03PM CDT
U.S. Silica (SLCA) is set to release its third-quarter 2014 results before the opening gong on Oct 29.
CCJ: 18.75 (+2.02), HBM: 7.47 (+0.52), NEM: 19.19 (+0.99), SLCA: 43.17 (+1.38)

Will Yamana Gold (AUY) Surprise This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 2:53PM CDT
Yamana Gold Inc. (AUY) is set to release its third-quarter 2014 results after the market closes on Oct 29. Last quarter, the mining company delivered a 66.67% positive surprise.
CCJ: 18.75 (+2.02), NEM: 19.19 (+0.99), AUY: 3.92 (+0.38), SLCA: 43.17 (+1.38)

Will Freeport (FCX) Keep the Earnings Streak Alive in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 4:22PM CDT
Freeport-McMoRan Inc. (FCX) is set to release its third-quarter 2014 results ahead of the bell on Oct 28. Last quarter, the mining company delivered an 18.37% positive surprise.
CCJ: 18.75 (+2.02), FCX: 28.34 (+0.77), NEM: 19.19 (+0.99), SLCA: 43.17 (+1.38)

Will Eaton Corporation (ETN) Earnings be a Letdown in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 4:10PM CDT
Eaton Corporation plc (ETN) is scheduled to report third-quarter 2014 results before the opening bell on Oct 29.
ASH: 109.81 (+1.10), CCJ: 18.75 (+2.02), ETN: 69.17 (+0.11), CE: 59.31 (-0.24)

Will Cliffs Natural (CLF) Surprise this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 2:43PM CDT
Cliffs Natural Resources Inc. (CLF) is set to release its third-quarter 2014 results after the market closes on Oct 27. Last quarter, the mining company delivered an 87.50% positive surprise.
CCJ: 18.75 (+2.02), HBM: 7.47 (+0.52), NEM: 19.19 (+0.99), CLF: 11.17 (+0.63)

Cameco Has Returned 10.5% Since SmarTrend Recommendation (CCJ)
Comtex SmarTrend(R) - Wed Oct 22, 11:11AM CDT
SmarTrend identified a Downtrend for Cameco (NYSE:CCJ) on August 7th, 2014 at $19.28. In approximately 3 months, Cameco has returned 10.52% as of today's recent price of $17.25.
CCJ: 18.75 (+2.02)

First Uranium Concentrate Produced from Ore Mined at Cigar Lake
Marketwired - Wed Oct 08, 3:13PM CDT
ALL AMOUNTS ARE STATED IN CDN $ (UNLESS NOTED)
CCJ: 18.75 (+2.02), CCO.TO: 21.24 (+2.11)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Innovent's IBI3001 Shows Promise in Phase 1 Trials

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

DigitalXForce Shakes Up GRC: AI-Infused X-ROC Launch

Turning Risk Management on Its Head Well, here's a company not just tinkering around the edges but flipping the script on Governance, Risk, and Compliance (GRC) with their latest rollout: DigitalXForce and its X-ROC. Yeah, it's yet another acronym to juggle, but don't roll your eyes just yet. This AI-driven beast isn't about occasional boardroom reports. No sir, it's a...

TORRAS Cases Balance Protection with Slim Design for 2026

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Clarins Dazzles Austin with Skin Longevity Event

Clarins Takes Austin by Storm Under the vast Austin sky, something remarkable unfolded as Clarins transformed the scene with a flashy rooftop affair that screamed innovation and elegance. They weren’t just showing off fancy bottles of beauty potion; they were stirring the pot, merging science with a splash of high-end glitz. This wasn’t just another product pitch—it...

Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Dr. Boonipat Inspires Future Women Surgeons at Texas Tech

Sowing Surgical Seeds in Lubbock In Lubbock, Texas, something meaningful unfolded—an event the big market players would hardly blink at, but a significant step for the future of medicine. Led by Dr. Thanapoom "Mo" Boonipat, the founder of FacePlus Plastic Surgery Institute, a unique suturing workshop provided premed students at Texas Tech University hands-on experience...

Borr Drilling's Rig Sinks, Uncertainty Looms Offshore

Unexpected Turn of Events at Sea Now here's a gut-punch nobody saw coming. Borr Drilling Limited (NYSE and OSE: BORR) got hit hard when their Prospector 5 drilling rig went under the waves offshore Gabon. This ain't no desk job dilemma; we're talking about a real-life offshore catastrophe. It all went down on October 24, 2026, when the rig experienced a punch through...

Gildan Activewear Faces Legal Battle Over Alleged Fraud

Investor Alert: Gildan's Legal Showdown Alright, here's a twist you didn't see coming—or maybe you did if you've been tracking the ticker tapes like a hawk. Gildan Activewear Inc. (NYSE:GIL) is stuck in the kind of hot water that can scald the bottom line. The Stakes: Racing Towards December 14 Marked on your calendar, December 14, is a date of some significance if...